KinergyCare is a Virginia-based startup and a Virginia Bio member that is requesting feedback from this community on a care coaching and coordination approach that focuses on the needs of patients with cardiovascular disease. We’re pioneering a new approach that combines patient data on health capabilities with a personalized intervention based on behavioral science. The result should be a more personalized clinical intervention and coaching approach that better ensures lasting behavioral change. We’re looking to talk with stakeholders such as cardiologists, nurses, care management teams, and administrators to learn more about the unmet needs. This outreach is part of our participation in the Spring cohort of the Roanoke Acceleration and Mentoring Program (RAMP), so we would really appreciate any help. Please help us by filling in this brief, 10 question survey. Also, if you have some guidance or can connect us with someone in your network that fits the above roles please contact KinergyCare CEO Art Spivy at aspivy@kinergycare.com or (571) 277-5373. Thanks for your help!
News
Recent News
02/05/2025
Project Vital bringing millions in funding to Roanoke-Blacksburg’s life sciences
The Roanoke-Blacksburg region is establishing itself as a biomedical research hub and medical device innovation center. About $5 million from the state could help move that work from labs to markets. Those millions will fund Project Vital: Virginia Innovations and Technology Advancements in Life Sciences. It’s a collaboration among the Roanoke-Blacksburg Innovation Alliance (formerly Verge), …
01/31/2025
AGC Pharma Chemicals announces expansion of HPAPI capabilities in Barcelona
AGC Pharma Chemicals, a leading innovator in pharmaceutical manufacturing with over 40 years of expertise in Contract Development Manufacturing Operations (CDMO) for small molecule APIs based in Barcelona (Spain) and Japan, announces a significant expansion of its High Potency Active Pharmaceutical Ingredients (HPAPI) capabilities, enabling seamless scale-up from grams to tons within a single integrated …
01/30/2025
OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant to Revolutionize Knee Pain Treatment
OrthoPreserve, a company developing orthopedic implant solutions, announced today it has been granted both a Breakthrough Device Designation and Total Product Life Cycle Advisory Program (TAP) enrollment from the U.S. Food & Drug Administration (FDA) for Defender, a meniscus replacement implant. The designation covers the use of the therapeutic medical device to treat patients who …